New England Journal of Medicine
Almirall’s paediatric registration of Ebglyss for atopic dermatitis gets EMA acceptance
Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood
Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis
This new option for patients allows for as few as six maintenance injections per year
Almirall celebrates new offices in China to advance innovation in dermatology
The company’s R&D and commercial expertise represent valuable capabilities for future Chinese partners
Sanofi’s amlitelimab shows positive results in atopic dermatitis
Newly released study data shows consistent reductions in disease severity
Galderma’s Nemluvio rapidly relieves atopic dermatitis and prurigo nodularis symptoms
Some patients found the treatment reduced itch and sleep disturbance within just two days
Almirall and Absci expand AI dermatological drug discovery partnership
The alliance has already led to the delivery of functional antibody leads against a difficult-to-drug target
Apogee Therapeutics’ atopic dermatitis candidate shows promise in phase 2 study
The inflammatory skin condition affects over 26 million people in the US
Eli Lilly/Almirall’s Ebglyss shows promise in atopic dermatitis patients with darker skin tones
The inflammatory skin condition occurs in approximately 7.3% of adults in the US
Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones
These are the first clinical study results for the drug in a large population of patients with darker skin tones
Galderma shares positive two-year results for Nemluvio in atopic dermatitis
The chronic inflammatory skin disease affects more than 230 million people worldwide
Almirall hosts Skin Academy to advance skin science and dermatology treatments
The conference will cover actinic keratosis, psoriasis, atopic dermatitis and other skin diseases
Amgen/Kyowa Kirin share promising phase 3 results for rocatinlimab in atopic dermatitis
The inflammatory skin disease affects up to 20% of children and 10% of adults worldwide